Sacubitril And Valsartan Tablet
Product Images NDC 13668-747

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Sacubitril And Valsartan (NDC 13668-747). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Torrent Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Image (Chemical Structure)

Image (Chemical Structure)
FDA Label Image

24 mg/26 mg (Container Label 24 26)

24 mg/26 mg (Container Label 24 26)
This text provides information about a medication containing 24 mg of sacubitril and 26 mg of valsartan. It includes instructions on storage conditions, keeping the drugs out of reach of children, and dispensing in a tight container with a child-resistant closure. The batch and expiration details are mentioned for serialization purposes. It also mentions the manufacturer and distributor details of the tablets. Dosage guidance is advised to be in accordance with the prescribing information provided. The tablets come in a pack of 500 and are intended for prescription use only.*
FDA Label Image

49 mg/51 mg (Container Label 49 51)

49 mg/51 mg (Container Label 49 51)
Each film-coated tablet contains 49 mg of sacubitril and 51 mg of valsartan. Keep this and all drugs out of the reach of children. Store at 20-25°C (68-77°F); excursions permitted between 15-30°C (59-86°F). Protect from moisture. Dispense in a tight container with a child-resistant closure. It is recommended to refer to the prescribing information for the usual dosage. Manufactured by TORRENT PHARMACEUTICALS LTD, Bharuch-392130, INDIA. Manufactured for TORRENT PHARMA INC, Basking Ridge, NJ 07920. This product comes in a package of 500 tablets, with the NDC 13668-635-05. The unvarnished area is intended for imprinting of batch and expiration date, as well as serialization information.*
FDA Label Image

97 mg/103 mg (Container Label 97 103)

97 mg/103 mg (Container Label 97 103)
This text provides information about a medicine containing sacubitril and valsartan in film-coated tablet form. It includes details on dosage, storage conditions, manufacturer information, and batch details such as NDC number. The text also emphasizes keeping the medication out of reach of children, storing it at specific temperatures, and protecting it from moisture. It also mentions a child-resistant closure and includes the manufacturer's location in India and the License Number.*
FDA Label Image

Image Description (Figure 01)

Image Description (Figure 01)
FDA Label Image

Image Description (Figure 02)

Image Description (Figure 02)
FDA Label Image

Image Description (Figure 03 A)

Image Description (Figure 03 A)
This is a description of the time to the first occurrence of cardiovascular death or heart failure hospitalizations in the PARADIGM-HF study. The statistical significance was shown by p<0.0001, with hazard ratio (HR) of 0.80 (95% CI: 0.73, 0.87). The study involved the use of sacubitril and valsartan. The graph displays the time since randomization (in days) on the x-axis and the occurrence of events on the y-axis.*
FDA Label Image

Image Description (Figure 03 B)

Image Description (Figure 03 B)
This is a statistical analysis of the time to occurrence of cardiovascular death in the PARADIGM-HF study. The Kaplan-Meier estimate of the cumulative failure rate and hazard ratio (HR) are provided. The graph shows the time since randomization in days and the number at risk in each group. The study compares the outcomes of patients receiving Valsartan versus Enalapril.*
FDA Label Image

Image Description (Figure 03 C)

Image Description (Figure 03 C)
This data appears to show the time to the first occurrence of heart failure hospitalizations in the PARADIGM-HF study, comparing Enalapril and Sacubitril/Valsartan. It includes a hazard ratio (HR) with a confidence interval of 95%. The graph ranges from 0 to 1260 days since randomization, displaying cumulative failure rates over time.*
FDA Label Image

Image Description (Figure 04)

Image Description (Figure 04)
FDA Label Image

Image Description (Figure 5)

Image Description (Figure 5)
FDA Label Image

Image Description (Figure 6)

Image Description (Figure 6)
This is not readable.*
FDA Label Image

Image Description (Figure 7)

Image Description (Figure 7)
This text provides information on hazard ratios for different medications in studies such as PARADIGM-HF and PARAGON-HF. It also includes left ventricular ejection fraction percentages at screening. This data could be used to evaluate the effectiveness of sacubitril and valsartan compared to enalapril and valsartan in treating heart failure.*
FDA Label Image
Image Description (Torrent Logo)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.